首页> 外文期刊>Canadian journal of anesthesia: Journal canadien d'anesthesie >Postoperative analgesia is not different after local vs systemic administration of meloxicam in patients undergoing inguinal hernia repair.
【24h】

Postoperative analgesia is not different after local vs systemic administration of meloxicam in patients undergoing inguinal hernia repair.

机译:接受腹股沟疝修补术的患者局部或全身服用美洛昔康后的术后镇痛没有区别。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To distinguish between local and systemic drug effects, we compared pain scores, analgesic consumption and plasma concentrations after local vs i.v. administration of meloxicam 7.5 mg in patients with inguinal hernia repair. METHODS: In a double-blind, randomized study 56 patients received either local or i.v. meloxicam 7.5 mg. Postoperative pain was assessed with a visual analogue scale (VAS) at rest, on mobilization, and on coughing, the need for supplementary analgesics (fentanyl i.v. and/or acetaminophen-codeine tablets) was recorded, and blood samples were drawn during 24 hr after meloxicam administration. RESULTS: No significant differences were found between groups with respect to pain scores, or in the consumption of supplementary analgesics. Following local application of meloxicam, the peak plasma concentration (C(max)) of 0.5 +/- 0.2 mg*L(-1) achieved after 1.8 +/- 0.5 hr was much lower than the C(max) of 2.5 +/- 0.9 mg*L(-1) achieved immediately after i.v. administration (P <0.05). Mean meloxicam plasma concentration after infiltration was significantly lower than after i.v. doses for the first three hours after administration (P <0.05). CONCLUSION: We showed no differences in pain scores and analgesic consumption between local and i.v. administration of meloxicam 7.5 mg during the first 24 hr after herniorrhaphy, while plasma concentration of meloxicam was lower after local administration. These results indicate a lack of difference in pain relief after concentrating meloxicam at the hernia wound or after achieving high blood levels rapidly (i.v.). Local administration of meloxicam may confer an advantage over systemic administration by eliciting lower incidences of systemic adverse effects.
机译:目的:为了区分局部和全身药物作用,我们比较了局部和静脉注射后的疼痛评分,止痛药消耗和血浆浓度。腹股沟疝修补术患者服用7.5 mg美洛昔康。方法:在一项双盲,随机研究中,有56例患者接受了局部或静脉内注射。美洛昔康7.5毫克在休息,运动和咳嗽时,使用视觉模拟量表(VAS)评估术后疼痛,记录是否需要补充镇痛药(芬太尼iv和/或对乙酰氨基酚可待因片),并在术后24小时内抽取血样美洛昔康给药。结果:在疼痛评分或补充镇痛药的消费方面,各组之间未发现显着差异。局部应用美洛昔康后,在1.8 +/- 0.5小时后达到的最高血浆浓度(C(max))为0.5 +/- 0.2 mg * L(-1),远低于2.5 + /的C(max)。 -静脉注射后立即达到0.9 mg * L(-1)给药(P <0.05)。渗透后美洛昔康的血浆平均浓度显着低于静脉注射后。给药后前三个小时的剂量(P <0.05)。结论:我们发现局部和静脉内在疼痛评分和止痛药消耗方面没有差异。在疝气治疗后的最初24小时内服用7.5 mg美洛昔康,而局部给药后美洛昔康的血浆浓度较低。这些结果表明在将美洛昔康集中在疝气伤口上或迅速达到高血药浓度后(i.v.),在缓解疼痛方面没有差异。美洛昔康的局部给药可通过引起较低的全身不良反应发生率而优于全身给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号